TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8229536

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin G (IVIG), 1 gm/kg per day for 2 consecutive days (n = 19)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral prednisone, starting at a dose of 4 mg/kg per day, tapering and discontinuation by day 21 (n = 18)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No therapy (n = 16)
Number of subjects: 53
Study: 2879389

Group type: EXPERIMENTAL
Intervention: Celiprolol (300 mg for 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg for 4 weeks)
Number of subjects: 0
Study: 30267112

Group type: EXPERIMENTAL
Intervention: User- and carer-informed training package
Number of subjects: 134

Group type: COMPARATOR
Intervention: Training intervention
Number of subjects: 134
Study: 28394087

Group type: EXPERIMENTAL
Intervention: DNA methylation at CpG site cg23196985
Number of subjects: 5515
Study: 25319061

Group type: EXPERIMENTAL
Intervention: Abituzumab 500 mg combined with cetuximab and irinotecan (arm A)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Abituzumab 1000 mg combined with cetuximab and irinotecan (arm B)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Cetuximab plus irinotecan alone (SoC, arm C)
Number of subjects: 216
Study: 23702231

Group type: EXPERIMENTAL
Intervention: hANP (carperitide)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 21889560

Group type: EXPERIMENTAL
Intervention: Switching group (paroxetine 20-40 mg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Continuing group (sertraline 50-100 mg)
Number of subjects: 132
Study: 19629664

Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Accelerometer (ACC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS) and Accelerometer (ACC)
Number of subjects: 20
Study: 17444378

Group type: EXPERIMENTAL
Intervention: Polarised light treatment (once daily for 10 minutes on sacral area and both heels)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No polarised light treatment (control group)
Number of subjects: 23
Study: 15173537

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) after surfactant administration (SURF‐NCPAP group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV) after surfactant administration (SURF‐MV group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NCPAP after surfactant administration (SURF‐NCPAP group)
Number of subjects: 0
Study: 11696708

Group type: EXPERIMENTAL
Intervention: Mechanical percussion and inversion
Number of subjects: 69

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 69
Study: 9158092

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination with recombinant gp160 (rgp160) or gp120 (rgp120)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8506453

Group type: EXPERIMENTAL
Intervention: Gammahydroxybutyrate (GHB), 60 mg/kg/night
Number of subjects: 24
Study: 3829910

Group type: EXPERIMENTAL
Intervention: Ascot preparation of procainamide hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Squibb preparation of procainamide hydrochloride
Number of subjects: 10
Study: 2575982

Group type: EXPERIMENTAL
Intervention: epanolol 200mg once daily
Number of subjects: 573

Group type: COMPARATOR
Intervention: metoprolol 100mg twice daily
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: epanolol
Number of subjects: 573

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 573
Study: 30794316

Group type: EXPERIMENTAL
Intervention: Tailored text message intervention
Number of subjects: 0
Study: 30601407

Group type: EXPERIMENTAL
Intervention: Circulating microparticles from patients with VHD before and after cardiac surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Circulating microparticles from age-matched control subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Circulating microparticles from patients with VHD before surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Circulating microparticles from patients with VHD after surgery
Number of subjects: 100
Study: 28390289

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg orally once daily
Number of subjects: 10
Study: 26939323

Group type: EXPERIMENTAL
Intervention: Huolong moxibustion, applied once a day for 3 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine traction combined with massage therapy, applied once a day for 3 weeks
Number of subjects: 65
Study: 23735418

Group type: EXPERIMENTAL
Intervention: Low serum magnesium (sMg) levels (<2.0 mg/dL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low intracellular magnesium (iMg) levels (<3.75 mg/dL erythrocytes)
Number of subjects: 0
Study: 21255610

Group type: EXPERIMENTAL
Intervention: NIM811 monotherapy (doses of 10 to 600 mg orally once or twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NIM811 (600 mg bid) in combination with pegylated interferon alpha (PEG‐IFN‐α)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PEG‐IFN alone
Number of subjects: 12
Study: 19317999

Group type: EXPERIMENTAL
Intervention: Selective internal radioembolization (SIR) for patients without venous thrombosis (20 patients)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Selective internal radioembolization (SIR) for patients with venous thrombosis (15 patients)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Best supportive care for untreated patients (17 patients, 10 with VT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: All groups (including treated and untreated)
Number of subjects: 52
Study: 16816014

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 120
Study: 15163494

Group type: EXPERIMENTAL
Intervention: High throughput RT-PCR (HTP RT-PCR)
Number of subjects: 4176

Group type: COMPARATOR
Intervention: Culture confirmation
Number of subjects: 4176
Study: 10961521

Group type: EXPERIMENTAL
Intervention: CHO-electrolyte solution (CE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study: 9278966

Group type: EXPERIMENTAL
Intervention: Unilateral condition (subject alone makes the decision)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multilateral condition (everyone participates in reward allocation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 8173195

Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 250 micrograms/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 500 micrograms/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 750 micrograms/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 1,000 micrograms/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at all dose levels
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 14
Study: 2868736

Group type: EXPERIMENTAL
Intervention: Thiopental loading added to standard therapy
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 262
Study: 30575560

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27224908

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (25-250 mg)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 24476454

Group type: EXPERIMENTAL
Intervention: Tropicamide 1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 90
Study: 23600541

Group type: EXPERIMENTAL
Intervention: Homozygous for variant alleles of ALOX5 promoter SP1 tandem repeat (rs59439148)
Number of subjects: 270

Group type: COMPARATOR
Intervention: All children
Number of subjects: 270
Study: 20197167

Group type: EXPERIMENTAL
Intervention: Bite wafer (BW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Over-the-counter analgesics (OTC)
Number of subjects: 0
Study: 18550582

Group type: EXPERIMENTAL
Intervention: Daily free distribution program
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multicomponent program (classroom curriculum and parental involvement)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study: 16409336

Group type: EXPERIMENTAL
Intervention: Pilot needle anchoring during wide bore needle puncture (group 2)
Number of subjects: 157
Study: 12242514

Group type: EXPERIMENTAL
Intervention: EPO plus G‐CSF
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: EPO plus GM‐CSF
Number of subjects: 361
Study: 9682041

Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate per day
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: 10 mg of alendronate per day
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Alendronate (both doses)
Number of subjects: 477
Study: 7897120

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 695

Group type: COMPARATOR
Intervention: No thrombolytic therapy (baseline ECG)
Number of subjects: 695
Study: 2482549

Group type: EXPERIMENTAL
Intervention: Org 10172 (750 anti-Xa units/day, 500 units bid, or 750 units bid)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections)
Number of subjects: 48
Study: 178852

Group type: EXPERIMENTAL
Intervention: Live attenuated respiratory syncytial virus ts‐1 vaccine administered intranasally at a low dose (100 TCID50)
Number of subjects: 25
Study: 31703434

Group type: EXPERIMENTAL
Intervention: C12 (0.3 kcal/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: C12+Trp (0.4 kcal/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trp (0.1 kcal/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 29957709

Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26418779

Group type: EXPERIMENTAL
Intervention: Regular mail + $1 bill
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Regular mail + $5 bill
Number of subjects: 608

Group type: COMPARATOR
Intervention: Emailed with a link to an online survey
Number of subjects: 608

Group type: COMPARATOR
Intervention: Regular mail
Number of subjects: 608
Study: 24703046

Group type: EXPERIMENTAL
Intervention: Fructosamine above the 95th percentile
Number of subjects: 12306

Group type: EXPERIMENTAL
Intervention: Glycated albumin above the 95th percentile
Number of subjects: 12306

Group type: EXPERIMENTAL
Intervention: Fructosamine
Number of subjects: 12306

Group type: EXPERIMENTAL
Intervention: Glycated albumin
Number of subjects: 12306

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 12306
Study: 21988334

Group type: COMPARATOR
Intervention: Tolvaptan 30 mg with ketoconazole 200 mg once daily for 3 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tolvaptan 240 mg with rifampicin 600 mg once daily for 7 days
Number of subjects: 38
Study: 19632972

Group type: EXPERIMENTAL
Intervention: Email communication with physicians
Number of subjects: 4059

Group type: EXPERIMENTAL
Intervention: Demographic factors (African Americans, Hispanics, men)
Number of subjects: 4059

Group type: EXPERIMENTAL
Intervention: Perception of physician's communication skills and enthusiasm
Number of subjects: 4059

Group type: EXPERIMENTAL
Intervention: Email usage
Number of subjects: 4059

Group type: EXPERIMENTAL
Intervention: Age factor
Number of subjects: 4059

Group type: EXPERIMENTAL
Intervention: Physician enthusiasm
Number of subjects: 4059
Study: 17935234

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (doses ≤8 mg/24 h)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Ropinirole (doses ≤12 mg/day)
Number of subjects: 561
Study: 15897937

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 335
Study: 12483368

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg on each day of chemotherapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 40
Study: 9616310

Group type: EXPERIMENTAL
Intervention: Antituberculous chemotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (no antituberculous chemotherapy)
Number of subjects: 130
Study: 8594015

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 2613389

Group type: EXPERIMENTAL
Intervention: Liquid paracetamol dosage form
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Solid paracetamol dosage form (tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Solid paracetamol dosage form (tablets) with meal enriched in dietary fiber
Number of subjects: 12

Group type: COMPARATOR
Intervention: Liquid and solid paracetamol dosage forms
Number of subjects: 12
Study: 870376

Group type: EXPERIMENTAL
Intervention: Fleet's Phospho‐Soda enema
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: bisacodyl (Dulcolax), 10 mg, by enema or suppository
Number of subjects: 10

Group type: COMPARATOR
Intervention: oral mannitol to induce diarrhea
Number of subjects: 10

Group type: COMPARATOR
Intervention: isotonic saline enema
Number of subjects: 10

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 10
Study: 31196803

Group type: EXPERIMENTAL
Intervention: Fluid bolus (saline or albumin)
Number of subjects: 3141

Group type: COMPARATOR
Intervention: No fluid bolus
Number of subjects: 3141
Study: 28831951

Group type: EXPERIMENTAL
Intervention: Milk protein concentrate (PRO, 4×20 g on exercise day and 20 g/d for the following 8 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Milk protein concentrate (PRO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 25948101

Group type: EXPERIMENTAL
Intervention: Dasotraline 8 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dasotraline 4 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24494295

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anesthesia group (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 21324520

Group type: EXPERIMENTAL
Intervention: Daily beclomethasone (twice daily, 40 μg per puff)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Combined (twice daily beclomethasone with beclomethasone plus albuterol as rescue)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Rescue beclomethasone (twice daily placebo with beclomethasone plus albuterol as rescue)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Placebo (twice daily placebo with placebo plus albuterol as rescue)
Number of subjects: 843
Study: 18573120

Group type: EXPERIMENTAL
Intervention: New protocol for postoperative calcium management with iPTH measurement at 4 hours postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard postoperative care)
Number of subjects: 50
Study: 17580440

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Quchi, Lieque, Yuji, Neiguan, Zusanli, Sanyinjiao, Taixi) once daily for 12 days
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group treated with anti-asthma drugs (Cromolyn sodium, Albuterol, fenoterol)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for moderate and severe asthma
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group treated with anti-asthma drugs
Number of subjects: 71
Study: 15458772

Group type: EXPERIMENTAL
Intervention: Stavir (Cipla Ltd, India; 40 mg capsule)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zerit (Bristol-Myers Squib, NJ, USA; 40 mg capsule)
Number of subjects: 24
Study: 12575376

Group type: EXPERIMENTAL
Intervention: Xuejie Jiawei Decoction No. I, one dose per day for 7 days, starting from the 2nd day after abortion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xuejie Jiawei Decoction No. II, one dose per day for 5 days, starting from the 11th day after abortion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, untreated
Number of subjects: 0
Study: 9622044

Group type: EXPERIMENTAL
Intervention: Clonidine plus neuroleptic (dosage of clonidine varied from 0.2 to 0.6 mg per day, neuroleptic averaged 34 mg per day of haloperidol equivalents)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo plus neuroleptic (neuroleptic averaged 34 mg per day of haloperidol equivalents)
Number of subjects: 12
Study: 1769029

Group type: EXPERIMENTAL
Intervention: Continuous patch application (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent application with 4 hours intervals (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent application with 6 hours intervals (Group C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: First dose of the nitroglycerin patch
Number of subjects: 24
Study: 6123129

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31276674

Group type: EXPERIMENTAL
Intervention: Fully-covered self-expanding metal stents (FCSEMSs)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Uncovered self-expanding metal stents (UCSEMSs)
Number of subjects: 119
Study: 28093604

Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil (5-FU) pretreatment for 7 days, twice daily before daylight-mediated photodynamic therapy (PDT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Daylight-mediated photodynamic therapy (PDT) alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both groups (5-FU + PDT and PDT alone)
Number of subjects: 24
Study: 25490525

Group type: EXPERIMENTAL
Intervention: Home-based walking exercise (40 min/day, 3 days/week for 12 weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 116
Study: 24909093

Group type: EXPERIMENTAL
Intervention: AZD1656 + glucagon
Number of subjects: 8

Group type: COMPARATOR
Intervention: AZD1656 alone
Number of subjects: 8
Study: 22392326

Group type: EXPERIMENTAL
Intervention: Rolls fortified with microencapsulated iron sulfate (4 mg iron each), offered once a day, five days a week for 24 weeks.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Rolls without fortification (control group).
Number of subjects: 173
Study: 20662314

Group type: EXPERIMENTAL
Intervention: Rosiglitazone maleate sustained-release floating microspheres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial tablets (control)
Number of subjects: 0
Study: 18363603

Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESA)
Number of subjects: 2498

Group type: COMPARATOR
Intervention: Indeterminate evidence of harm from ESA
Number of subjects: 2498
Study: 15750513

Group type: EXPERIMENTAL
Intervention: Contreet Foam dressing
Number of subjects: 27
Study: 12676472

Group type: EXPERIMENTAL
Intervention: PGME vapour at 150 ppm
Number of subjects: 12

Group type: COMPARATOR
Intervention: PGME vapour at 100 ppm
Number of subjects: 12

Group type: COMPARATOR
Intervention: PGME vapour at 0 ppm
Number of subjects: 12
Study: 10686660

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg orally daily for 10 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 9
Study: 9374089

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 104

Group type: COMPARATOR
Intervention: FAC (5-fluorouracil/doxorubicin/cyclophosphamide)
Number of subjects: 104
Study: 1549650

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (d-FF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-amphetamine (d-amp)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (d-FF) + d-amphetamine (d-amp)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: l-fenfluramine (l-FF) + d-amphetamine (d-amp)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: l-fenfluramine (l-FF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-amphetamine (d-amp) + d-fenfluramine (d-FF)
Number of subjects: 12
Study: 2862892

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31615801

Group type: EXPERIMENTAL
Intervention: HIGH-FLOW nasal oxygenation
Number of subjects: 530

Group type: COMPARATOR
Intervention: LOW-FLOW nasal oxygenation
Number of subjects: 530
Study: 29197091

Group type: EXPERIMENTAL
Intervention: Cognitive therapy for PTSD (CT-PTSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (waitlist control)
Number of subjects: 0
Study: 27575854

Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (LED blue light device with photo-converter chromophores), treated for 6 weeks (twice weekly)
Number of subjects: 0
Study: 25391047

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 182
Study: 22459647

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture without electrical stimulation (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional treatment (group A)
Number of subjects: 0
Study: 19692415

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (ORAFTI®Synergy 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0